Diagnostics company Bio-Rad has been sued by the California Institute of Technology for allegedly misusing the school's patented technology for analyzing biological samples.

HERCULES, Calif. - Bio-Rad Laboratories, Inc. (NYSE:BIO) reported fourth-quarter results that fell short of analyst ...

Bio-Rad Laboratories, Inc. BIO recently entered into a binding agreement to purchase all equity interests in Stilla Technologies ("Stilla"). Stilla’s next-generation digital PCR solutions complement ...

Bio-Rad Laboratories, Inc. manufactures and distributes life science research and clinical diagnostic products in the United States, Europe, Asia, Canada, and Latin America. It operates through ...

Reports Q4 revenue $667.5M, consensus $679.75M. Norman Schwartz, Bio-Rad’s (BIO) Chairman and CEO, commented: “Bio-Rad demonstrated ...

Bio-Rad Laboratories, Inc. (NYSE: BIO and BIO.B), a global leader in life science research and clinical diagnostics products, today announced that the company has entered into a binding offer to ...

Bio-Rad Laboratories, Inc.’s BIO solid momentum in the QX600 Droplet Digital PCR (ddPCR) platform is poised to help it grow in the upcoming quarters. The clinical diagnostics business sees ...

(RTTNews) - OncoCyte Corp. (OCX), a diagnostics technology ... to close around February 10. Bio-Rad will provide additional financial support for an upcoming clinical trial and commercialization ...

Highlights,Bio-Rad Laboratories (BIO) drives innovation in life sciences and clinical diagnostics with a diversified product ...

Bio-Rad Laboratories, Inc. manufactures and distributes life science research and clinical diagnostic products in the United States, Europe, Asia, Canada, and Latin America. It operates through ...

Bio-Rad Laboratories ... It operates through the Life Science and Clinical Diagnostics segments. The Life Science segment develops, manufactures, and markets reagents, apparatus, and laboratory ...